DIET DRUG SETTLEMENT FACT SHEET

Following are pertinent facts related to the nationwide class action settlement of claims against American Home Products (“AHP”) and other proposed Released Parties arising from the marketing, sale, distribution and use of the diet drugs Pondimin and Redux.

SETTLEMENT HIGHLIGHTS

• Includes all individuals who consumed, for any length of time, Pondimin and/or Redux, alone or in combination with phentermine. The combination of Pondimin and/or Redux and phentermine was popularly known as Fen-Phen.
  
• Provides medical monitoring as well as compensation for injury through two funds which could total up to $4.83 billion.
  
• Fund A underwrites medical monitoring, treatment, compensation and research/education.
  
• Fund B underwrites compensation through a Claims Matrix based upon severity of injury and age.
  
• Class Members could receive up to approximately $1.5 million (adjusted upward on an annual basis), depending on the extent of their injuries and their ages.
  
• Class Members have three opportunities to exclude themselves from the Settlement and pursue individual legal remedies.
  
• Class Members may elect an Accelerated Implementation Option which allows them to receive the benefits of the Settlement at an early date and regardless of whether the Settlement as a whole receives final judicial approval.

Class Members
The Settlement Class consists of all persons in the United States, its possessions and territories who ingested Pondimin and/or Redux and certain other person asserting the right to sue AHP (Derivative Claimants). All claims against AHP on behalf of these individuals are settled, except claims for primary pulmonary hypertension.

There are five subclasses, which include persons who:

• Ingested Pondimin and/or Redux for 60 days or less but were not diagnosed as FDA Positive as of September 30, 1999 – Subclass 1(a).
  
• Ingested Pondimin and/or Redux for more than 60 days but were not diagnosed as FDA Positive as of September 30, 1999 – Subclass 1(b).
  
• Ingested Pondimin and/or Redux for 60 days or less and were diagnosed as FDA Positive as of September 30, 1999 – Subclass 2(a).
  
• Ingested Pondimin and/or Redux for more than 60 days and were diagnosed as FDA Positive as of September 30, 1999 – Subclass 2(b).
  
• Diagnosed as having Mild Mitral Regurgitation as of the close of the screening period as provided in the Settlement and who are not otherwise FDA Positive by virtue of having mild or greater aortic valvular regurgitation – Subclass 3.

For further information please e-mail M. J. Tytran at lawyers1@c2law.com. Please provide the following information in your e-mail:

• Name
• Address
• Phone Number
• Brand name of medication you took (if known)
  
  Diagnosis:
  
• heart valve defect (leaking valve) or
• primary pulmonary hypertension